Carcinogenesis, Vol. 22, No. 8, 1271-1279,
August 2001
© 2001 Oxford University Press
CARCINOGENESIS |
Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis
1 Department of Urology,
2 Department of Pathology and
3 Department of Biochemistry, New York University School of Medicine, 540 First Avenue, New York, NY 10016 and
4 Department of Pathology, University of Michigan, Ann Arbor, MI, USA
B cell translocation gene 2 (BTG2) is a p53 target that negatively regulates cell cycle progression in response to DNA damage and other stress. The objective of this study was to examine the expression, regulation and tumor suppressor properties of BTG2 in prostate cells. By immunohistochemistry BTG2 protein was detected in ~50% of basal cells in benign glands from the peripheral zone of the human prostate. BTG2 was expressed in all hyperproliferative atrophic peripheral zone lesions examined (simple atrophy, post-atrophic hyperplasia and proliferative inflammatory atrophy), but was undetectable or detectable at very low levels in the hyperproliferative epithelial cells of HGPIN and prostate cancer. BTG2 mRNA was detected in non-malignant prostate epithelial (PE) cells and in LNCaP cells, but not in PC-3 cells, consistent with p53-dependent regulation. In PE cells BTG2 protein was detected in areas of cell confluence by immunohistochemistry. BTG2 protein in LNCaP cells was undetectable by immunohistochemistry but was detected by immunoblotting at 8- to 9-fold lower levels than in PE cells. BTG2 protein levels were shown to be regulated by the ubiquitin–proteosome system. Forced expression of BTG2 in PC-3 cells was accompanied by a decreased rate of cell proliferation and decreased tumorigenicity of these cells in vivo. Taken together, these findings suggest that BTG2 functions as a tumor suppressor in prostate cells that is activated by cell quiescence, cell growth stimuli as part of a positive feedback mechanism and in response to DNA damage or other cell stress. The low steady-state levels of BTG2 protein in HGPIN and prostate cancer, a potential consequence of increased proteosomal degradation, may have important implications in the initiation and progression of malignant prostate lesions. Furthermore, these findings suggest that a significant component of the p53 G1 arrest pathway might be inactivated in prostate cancer even in the absence of genetic mutations in p53.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. C. Kim, M. S. Ryu, S. P. Oh, and I. K. Lim TIS21/BTG2 Negatively Regulates Estradiol-Stimulated Expansion of Hematopoietic Stem Cells by Derepressing Akt Phosphorylation and Inhibiting mTOR Signal Transduction Stem Cells, September 1, 2008; 26(9): 2339 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Farioli-Vecchioli, M. Tanori, L. Micheli, M. Mancuso, L. Leonardi, A. Saran, M. T. Ciotti, E. Ferretti, A. Gulino, S. Pazzaglia, et al. Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3 FASEB J, July 1, 2007; 21(9): 2215 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Donato, J. H. Suh, and N. Noy Suppression of Mammary Carcinoma Cell Growth by Retinoic Acid: the Cell Cycle Control Gene Btg2 Is a Direct Target for Retinoic Acid Receptor Signaling Cancer Res., January 15, 2007; 67(2): 609 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kawakubo, E. Brachtel, T. Hayashida, G. Yeo, J. Kish, A. Muzikansky, P. D. Walden, and S. Maheswaran Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res., July 15, 2006; 66(14): 7075 - 7082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lopez-Rios, S. Chuai, R. Flores, S. Shimizu, T. Ohno, K. Wakahara, P. B. Illei, S. Hussain, L. Krug, M. F. Zakowski, et al. Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. Cancer Res., March 15, 2006; 66(6): 2970 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Boiko, S. Porteous, O. V. Razorenova, V. I. Krivokrysenko, B. R. Williams, and A. V. Gudkov A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation Genes & Dev., January 15, 2006; 20(2): 236 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Tilton, L. G. Gerwick, J. D. Hendricks, C. S. Rosato, G. Corley-Smith, S. A. Givan, G. S. Bailey, C. J. Bayne, and D. E. Williams Use of a Rainbow Trout Oligonucleotide Microarray to Determine Transcriptional Patterns in Aflatoxin B1-Induced Hepatocellular Carcinoma Compared to Adjacent Liver Toxicol. Sci., December 1, 2005; 88(2): 319 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D M Peehl Primary cell cultures as models of prostate cancer development Endocr. Relat. Cancer, March 1, 2005; 12(1): 19 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Park, Y. J. Lee, H.-J. Lee, T. Seki, K.-H. Hong, J. Park, H. Beppu, I. K. Lim, J.-W. Yoon, E. Li, et al. B-Cell Translocation Gene 2 (Btg2) Regulates Vertebral Patterning by Modulating Bone Morphogenetic Protein/Smad Signaling Mol. Cell. Biol., December 1, 2004; 24(23): 10256 - 10262. [Abstract] [Full Text] [PDF]
|
|